Whole exome sequencing predicts whether patients respond to cancer immunotherapy
Immunotherapy, such as immune checkpoint inhibitors, has changed the treatment of advanced cancers. Unlike chemotherapy which kills cancer cells, these drugs help the immune system to find and destroy the cancer cells themselves. Unfortunately, only a subset of patients respond to immune checkpoint inhibitors in the long term; and these treatments can be expensive and with side effects. Researchers have developed a two-step approach using whole-exome sequencing to target genes and pathways that predict whether cancer patients will respond to immunotherapy. Studies published in Nature Communication and conducted by researchers at New York University, Weill Cornell Medicine, and the New York Genome Center, illustrates how using whole-exome sequencing can better predict treatment response than current laboratory tests. “Can we better predict who will benefit from immunotherapy? Scientists have developed a variety of biomarkers that help anticipate immunotherapy treatment responses, b